{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:27:13Z","timestamp":1782487633710,"version":"3.54.5"},"reference-count":57,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"CIORA"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.autrev.2018.01.019","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T01:19:24Z","timestamp":1525310364000},"page":"683-693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"17","author":[{"given":"Lillian","family":"Barra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pagnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2018.01.019_bb0005","doi-asserted-by":"crossref","first-page":"919","DOI":"10.7326\/0003-4819-120-11-199406010-00004","article-title":"Takayasu arteritis","volume":"120","author":"Kerr","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2018.01.019_bb0010","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1161\/CIRCULATIONAHA.114.012547","article-title":"Current clinical features of new patients with Takayasu arteritis observed from cross-country research in Japan: age and sex specificity","volume":"132","author":"Watanabe","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2018.01.019_bb0015","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/rheumatology\/ket238","article-title":"Impaired quality of life, disability and mental health in Takayasu's arteritis","volume":"52","author":"Yilmaz","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2018.01.019_bb0020","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.mayocp.2013.04.025","article-title":"Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients","volume":"88","author":"Schmidt","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2018.01.019_bb0025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2008.088351","article-title":"EULAR recommendations for the management of large vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.01.019_bb0030","first-page":"474","article-title":"Japanese circulation society","volume":"75","author":"Guideline for management of vasculitis syndrome (JCS 2008)","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.autrev.2018.01.019_bb0035","article-title":"Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: single centre experience from a large tertiary care teaching hospital in southern India","author":"Goel","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.019_bb0040","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jjcc.2016.07.009","article-title":"Effects of immunosuppressive and biological agents on refractory Takayasu arteritis patients unresponsive to glucocorticoid treatment","volume":"69","author":"Ohigashi","year":"2017","journal-title":"J Cardiol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0045","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/rheumatology\/ket320","article-title":"Management of Takayasu arteritis: a systematic review","volume":"53","author":"Keser","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2018.01.019_bb0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0055","first-page":"1","article-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses","author":"Wells","year":"2013","journal-title":"Ottawa Hosp Res Inst"},{"key":"10.1016\/j.autrev.2018.01.019_bb0060","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.autrev.2018.01.019_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.autrev.2018.01.019_bb0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/0003-4819-103-1-121","article-title":"Takayasu's arteritis and its therapy","volume":"103","author":"Shelhamer","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2018.01.019_bb0075","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jpeds.2006.10.059","article-title":"Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate","volume":"150","author":"Ozen","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.autrev.2018.01.019_bb0080","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.1780370420","article-title":"Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate","volume":"37","author":"Hoffman","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.019_bb0085","first-page":"S27","article-title":"Response of takayasu arteritis (TA) to prednisolone and methotrexate: an open label study","volume":"8","author":"GY","year":"2013","journal-title":"Indian J Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0090","first-page":"12","article-title":"Takaysu arteritis treatment in children","volume":"2014","author":"Kostina","year":"2014","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0095","first-page":"1793","article-title":"Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis","volume":"30","author":"Valsakumar","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10067-009-1333-6","article-title":"Mycophenolate mofetil in Takayasu's arteritis","volume":"29","author":"Goel","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0105","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s10067-007-0596-z","article-title":"Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis","volume":"26","author":"Shinjo","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/03009742.2011.633553","article-title":"Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study","volume":"41","author":"de Souza","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0115","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/art.20300","article-title":"Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis","volume":"50","author":"Hoffman","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.01.019_bb0120","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/ard.2008.093260","article-title":"Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up","volume":"67","author":"Molloy","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.01.019_bb0125","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/rheumatology\/ker380","article-title":"Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study","volume":"51","author":"Mekinian","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2018.01.019_bb0130","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/acr.21636","article-title":"Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup","volume":"64","author":"Schmidt","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2018.01.019_bb0135","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.autrev.2011.11.025","article-title":"Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature","volume":"11","author":"Comarmond","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.019_bb0140","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s10067-013-2380-6","article-title":"Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature","volume":"32","author":"Novikov","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0145","first-page":"922","article-title":"Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab","volume":"30","author":"Quartuccio","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0150","article-title":"Efficacy of anti-TNF therapy in 15 patients with refractory takayasu's arteritis: long term unicentric follow-up","volume":"71","author":"T","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.01.019_bb0155","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/0976-500X.136101","article-title":"Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis","volume":"5","author":"Serra","year":"2014","journal-title":"J Pharmacol Pharmacother"},{"key":"10.1016\/j.autrev.2018.01.019_bb0160","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.114.014321","article-title":"Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients","volume":"132","author":"Mekinian","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2018.01.019_bb0165","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1316-y","article-title":"TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study","volume":"19","author":"Gudbrandsson","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2018.01.019_bb0170","first-page":"56","article-title":"Retrospective study of biologic agents in Takayasu arteritis","author":"NP","year":"2017","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.autrev.2018.01.019_bb0175","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.autrev.2013.06.019","article-title":"Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review","volume":"12","author":"Abisror","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.019_bb0180","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3899\/jrheum.130536","article-title":"Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center","volume":"40","author":"Tombetti","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0185","first-page":"11","article-title":"Tocillizumab for patients with takayasu arteritis in childhood refractory to conventional therapy","author":"Yamazaki","year":"2013","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0190","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/RHU.0000000000000098","article-title":"Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis","volume":"20","author":"Canas","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0195","first-page":"S44","article-title":"Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review","volume":"34","author":"Loricera","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2018.01.019_bb0200","first-page":"171","article-title":"The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis","volume":"35","author":"Zhou","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0205","first-page":"S15","article-title":"Long term outcome of tocilizumab therapy for management of Takayasu arteritis","volume":"12","author":"Goel","year":"2017","journal-title":"Indian J Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0210","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kex249","article-title":"Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature","author":"Pazzola","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2018.01.019_bb0215","first-page":"403","article-title":"Arteritis: clinical features and treatment outcome in 16 pediatric patients","volume":"29","author":"BSBAZDDF","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0220","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s12026-017-8917-z","article-title":"Curcumin improves treatment outcome of Takayasu arteritis patients by reducing TNF-alpha: a randomized placebo-controlled double-blind clinical trial","volume":"65","author":"Shao","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2018.01.019_bb0225","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.imbio.2016.10.008","article-title":"Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: a randomized double-blind and placebo-controlled trial","volume":"222","author":"Shi","year":"2017","journal-title":"Immunobiology"},{"key":"10.1016\/j.autrev.2018.01.019_bb0230","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/art.40037","article-title":"A randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.autrev.2018.01.019_bb0235","article-title":"Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)","author":"Nakaoka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.01.019_bb0240","first-page":"403","article-title":"Takayasu arteritis: clinical features and treatment outcome in 16 pediatric patients","volume":"29","author":"B","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0245","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/1756-185X.12220","article-title":"Rapid control of disease activity by tocilizumab in 10 \u201cdifficult-to-treat\u201d cases of Takayasu arteritis","volume":"16","author":"Goel","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2018.01.019_bb0250","first-page":"671","article-title":"Birmingham Vasculitis activity score (BVAS) in systemic necrotizing vasculitis","volume":"87","author":"Luqmani","year":"1994","journal-title":"QJM"},{"key":"10.1016\/j.autrev.2018.01.019_bb0255","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/OARRR.S132080","article-title":"Variations in the clinical practice of physicians managing Takayasu arteritis: a nationwide survey","volume":"9","author":"Barra","year":"2017","journal-title":"Open Access Rheumatol Res Rev"},{"key":"10.1016\/j.autrev.2018.01.019_bb0260","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1452-4","article-title":"Childhood Takayasu arteritis: disease course and response to therapy","volume":"19","author":"Aeschlimann","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2018.01.019_bb0265","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/03009742.2015.1060521","article-title":"Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application","volume":"45","author":"Terao","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0270","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/BOR.0000000000000129","article-title":"Outcome measures for Takayasu's arteritis","volume":"27","author":"Aydin","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2018.01.019_bb0275","article-title":"Imaging modalities for the diagnosis and disease activity assessment of Takayasu's arteritis: a systematic review and meta-analysis","author":"Barra","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.01.019_bb0280","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/rheumatology\/ket128","article-title":"Development and initial validation of the Indian Takayasu clinical activity score (ITAS2010)","volume":"52","author":"Misra","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2018.01.019_bb0285","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.3899\/jrheum.161467","article-title":"Development of a Core set of outcome measures for large-vessel Vasculitis: report from OMERACT 2016","volume":"44","author":"Sreih","year":"2017","journal-title":"J Rheumatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218301083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218301083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T12:53:08Z","timestamp":1720270388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997218301083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1568997218301083"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2018.01.019","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2018.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}